Compare Stocks: THRD, JANX, OMER, and GERN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GERN Geron	$1.47 -4.2%	$1.38	$1.04 ▼ $2.01	$986.20M	0.61	10.77 million shs	11.15 million shs
JANX Janux Therapeutics	$16.12 +0.8%	$15.30	$12.12 ▼ $35.34	$978.19M	2.5	717,862 shs	441,517 shs
OMER Omeros	$17.19 -0.9%	$10.89	$3.94 ▼ $18.14	$1.26B	2.54	2.17 million shs	3.67 million shs
THRD Third Harmonic Bio	$5.38	$0.00	$0.00 ▼ $0.00	$242.80M	2.12	247,013 shs	N/A

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GERN Geron	-3.92%	-0.68%	+3.52%	+13.95%	+2.80%
JANX Janux Therapeutics	+0.75%	+1.70%	+0.56%	+16.05%	-35.42%
OMER Omeros	-0.92%	+29.74%	+65.77%	+40.33%	+302.58%
THRD Third Harmonic Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GERN Geron	$1.47 -4.2%	$1.38	$1.04 ▼ $2.01	$986.20M	0.61	10.77 million shs	11.15 million shs
JANX Janux Therapeutics	$16.12 +0.8%	$15.30	$12.12 ▼ $35.34	$978.19M	2.5	717,862 shs	441,517 shs
OMER Omeros	$17.19 -0.9%	$10.89	$3.94 ▼ $18.14	$1.26B	2.54	2.17 million shs	3.67 million shs
THRD Third Harmonic Bio	$5.38	$0.00	$0.00 ▼ $0.00	$242.80M	2.12	247,013 shs	N/A

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GERN Geron	-3.92%	-0.68%	+3.52%	+13.95%	+2.80%
JANX Janux Therapeutics	+0.75%	+1.70%	+0.56%	+16.05%	-35.42%
OMER Omeros	-0.92%	+29.74%	+65.77%	+40.33%	+302.58%
THRD Third Harmonic Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GERN Geron	2.20	Hold	$4.00	172.11% Upside
JANX Janux Therapeutics	2.50	Moderate Buy	$37.58	133.15% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	121.06% Upside
THRD Third Harmonic Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest THRD, JANX, OMER, and GERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
8/7/2026	JANX Janux Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $55.00
8/5/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/27/2026	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	OMER Omeros	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/9/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $33.00
6/25/2026	JANX Janux Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00 ➝ $26.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GERN Geron	$183.88M	5.14	N/A	N/A	$0.34 per share	4.32
JANX Janux Therapeutics	$10M	98.56	N/A	N/A	$15.18 per share	1.06
OMER Omeros	N/A	N/A	$1.85 per share	9.27	($0.71) per share	N/A
THRD Third Harmonic Bio	N/A	N/A	N/A	N/A	$6.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GERN Geron	-$83.50M	-$0.11	N/A	24.50	N/A	-34.17%	-24.48%	-10.30%	N/A
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	N/A
OMER Omeros	-$3.35M	$0.70	13.43	47.75	N/A	N/A	-164.92%	69.41%	N/A
THRD Third Harmonic Bio	-$45.47M	-$0.62	N/A	N/A	N/A	N/A	-19.27%	-18.67%	N/A

Latest THRD, JANX, OMER, and GERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GERN Geron	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
THRD Third Harmonic Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GERN Geron	0.55	6.91	5.16
JANX Janux Therapeutics	N/A	16.35	16.35
OMER Omeros	N/A	1.95	3.03
THRD Third Harmonic Bio	N/A	54.10	54.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GERN Geron	73.71%
JANX Janux Therapeutics	75.39%
OMER Omeros	48.79%
THRD Third Harmonic Bio	93.95%

Insider Ownership

Company	Insider Ownership
GERN Geron	1.71%
JANX Janux Therapeutics	7.90%
OMER Omeros	10.50%
THRD Third Harmonic Bio	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
OMER Omeros	210	72.38 million	64.78 million	Optionable
THRD Third Harmonic Bio	N/A	45.13 million	41.61 million	No Data

THRD, JANX, OMER, and GERN Headlines

Recent News About These Companies

THRD Share News Today

June 25, 2026 | uk.investing.com

Third Harmonic Bio to Delist from Nasdaq

July 31, 2025 | tipranks.com

Third Harmonic Bio, Inc. (THRD) Cash Flow - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Third Harmonic Bio Stock (NASDAQ:THRD), Insider Trading Activity

July 11, 2025 | benzinga.com

Third Harmonic Bio Inc News (THRD) - Investing.com

July 3, 2025 | investing.com

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

June 12, 2025 | globenewswire.com

Northeast Dominates 2025 Highest Income Rankings, Study Says: See Where Your State Stands

June 9, 2025 | msn.com

Third Harmonic Bio plans to liquidate the company, sell urticaria treatment

April 14, 2025 | msn.com

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered

April 14, 2025 | msn.com

Third Harmonic Bio Announces Plan of Liquidation and Dissolution

April 14, 2025 | globenewswire.com

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

March 27, 2025 | globenewswire.com

Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 4, 2025 | zacks.com

Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?

February 14, 2025 | zacks.com

Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)

February 14, 2025 | zacks.com

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

February 11, 2025 | globenewswire.com

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

November 25, 2024 | globenewswire.com

Apple making foray into smart home IP camera market, says analyst Ming-Chi Kuo

November 13, 2024 | finance.yahoo.com

Updates to the British Virgin Islands Anti-Money Laundering regime and changes for MLROs

November 12, 2024 | jdsupra.com

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade

November 11, 2024 | zacks.com

(LEAD) Netmarble swings to black in Q3 on steady-selling titles

November 8, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

THRD, JANX, OMER, and GERN Company Descriptions

Geron NASDAQ:GERN

$1.47 -0.07 (-4.23%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.46 -0.01 (-0.68%)

As of 08/14/2026 07:46 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Janux Therapeutics NASDAQ:JANX

$16.12 +0.12 (+0.75%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.12 0.00 (0.00%)

As of 08/14/2026 07:56 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Omeros NASDAQ:OMER

$17.19 -0.16 (-0.92%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$17.28 +0.09 (+0.54%)

As of 08/14/2026 07:59 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Third Harmonic Bio NASDAQ:THRD

TF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THRD, JANX, OMER, and GERN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THRD, JANX, OMER, and GERN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THRD, JANX, OMER, and GERN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

THRD, JANX, OMER, and GERN Company Descriptions

Geron NASDAQ:GERN

Janux Therapeutics NASDAQ:JANX

Omeros NASDAQ:OMER

Third Harmonic Bio NASDAQ:THRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THRD, JANX, OMER, and GERN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THRD, JANX, OMER, and GERN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THRD, JANX, OMER, and GERN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

THRD, JANX, OMER, and GERN Company Descriptions

Geron NASDAQ:GERN

Janux Therapeutics NASDAQ:JANX

Omeros NASDAQ:OMER

Third Harmonic Bio NASDAQ:THRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools